March 04, 2020
BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced the appointment of David Colleran to the newly created position of Executive Vice President, General Counsel and Corporate Secretary. In this new role, Mr. Colleran will lead the Company’s global legal organization, including corporate governance and compliance.
“We are delighted to welcome another strong leader to Anika,” said Cheryl Blanchard, Ph.D., interim Chief Executive Officer of Anika Therapeutics. “David has a proven record leading corporate legal and governance activities for global medical device and biotech companies, and his extensive experience in mergers and acquisitions, strategic alliances, intellectual property, and regulatory affairs will be invaluable to Anika as we continue to execute on our five-year strategic plan.” 
“I am thrilled to join Anika’s executive team at this very exciting stage in the Company’s evolution,” said David Colleran, Executive Vice President, General Counsel and Corporate Secretary of Anika Therapeutics. “Anika is well-positioned to bring innovative solutions to patients around the world, and I look forward to contributing to the Company’s continued growth.”
Prior to joining Anika, Mr. Colleran served as Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer at Insulet Corporation, a publicly traded, global medical device and drug delivery company. Prior to Insulet, he held the role of Vice President and General Counsel at Covidien, a global manufacturer of medical devices and supplies acquired by Medtronic, and Corporate Counsel at Ocean Spray Cranberries. Mr. Colleran began his career as a corporate attorney at Choate, Hall & Stewart. He received a Bachelor of Arts in Political Science from Boston College and a Juris Doctor from Boston College Law School. Click here to view his full bio.
About Anika Therapeutics
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated joint preservation and regenerative therapies company based in Bedford, Massachusetts. Anika is committed to delivering therapies to improve the lives of patients across a continuum of care from osteoarthritis pain management to joint preservation and restoration. The Company has over two decades of global expertise commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology platform. For more information about Anika, please visit www.anikatherapeutics.com.
Contacts
For Investor Inquiries:
Anika Therapeutics, Inc.
Sylvia Cheung, 781-457-9000
Chief Financial Officer
investorrelations@anikatherapeutics.com
For Media Inquiries:
W2O Group
Jeremy Berrington, 312-241-1995
jberrington@w2ogroup.com